Titre : Granulomatose avec polyangéite

Granulomatose avec polyangéite : Questions médicales fréquentes

Termes MeSH sélectionnés :

Early Detection of Cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Granulomatose avec polyangéite : Questions médicales les plus fréquentes", "headline": "Granulomatose avec polyangéite : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Granulomatose avec polyangéite : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-23", "dateModified": "2025-02-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Granulomatose avec polyangéite" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles", "url": "https://questionsmedicales.fr/mesh/D056648", "about": { "@type": "MedicalCondition", "name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles", "code": { "@type": "MedicalCode", "code": "D056648", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20.111.193" } } }, "about": { "@type": "MedicalCondition", "name": "Granulomatose avec polyangéite", "alternateName": "Granulomatosis with Polyangiitis", "code": { "@type": "MedicalCode", "code": "D014890", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Benjamin Terrier", "url": "https://questionsmedicales.fr/author/Benjamin%20Terrier", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France benjamin.terrier@aphp.fr." } }, { "@type": "Person", "name": "Xavier Puéchal", "url": "https://questionsmedicales.fr/author/Xavier%20Pu%C3%A9chal", "affiliation": { "@type": "Organization", "name": "Centre de Référence des Maladies Systémiques Auto-immunes rares, Université Paris Descartes, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris, France. Electronic address: xavier.puechal@aphp.fr." } }, { "@type": "Person", "name": "Christian Pagnoux", "url": "https://questionsmedicales.fr/author/Christian%20Pagnoux", "affiliation": { "@type": "Organization", "name": "Vasculitis Clinic, Division of Rheumatology, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada." } }, { "@type": "Person", "name": "Roman Yatsyshyn", "url": "https://questionsmedicales.fr/author/Roman%20Yatsyshyn", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine #1, Clinical Immunology and Allergology Named After Academician Ye. M. Neiko, Ivano-Frankivsk National Medical University, Halytska str. 2, Ivano-Frankivsk, 76000, Ukraine." } }, { "@type": "Person", "name": "Olena Zimba", "url": "https://questionsmedicales.fr/author/Olena%20Zimba", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers.", "datePublished": "2023-07-20", "url": "https://questionsmedicales.fr/article/37511475", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms241411715" } }, { "@type": "ScholarlyArticle", "name": "A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.", "datePublished": "2023-03-07", "url": "https://questionsmedicales.fr/article/36894035", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1053/j.gastro.2023.02.044" } }, { "@type": "ScholarlyArticle", "name": "Early detection of cancer therapy cardiotoxicity by radionuclide angiography: An update.", "datePublished": "2023-02-28", "url": "https://questionsmedicales.fr/article/36855007", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12350-023-03202-w" } }, { "@type": "ScholarlyArticle", "name": "Optimal age to stop prostate cancer screening and early detection.", "datePublished": "2023-08-19", "url": "https://questionsmedicales.fr/article/37598870", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jcpo.2023.100443" } }, { "@type": "ScholarlyArticle", "name": "Serum IgG N-glycans enable early detection and early relapse prediction of colorectal cancer.", "datePublished": "2022-10-03", "url": "https://questionsmedicales.fr/article/36121650", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ijc.34298" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système immunitaire", "item": "https://questionsmedicales.fr/mesh/D007154" }, { "@type": "ListItem", "position": 3, "name": "Maladies auto-immunes", "item": "https://questionsmedicales.fr/mesh/D001327" }, { "@type": "ListItem", "position": 4, "name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles", "item": "https://questionsmedicales.fr/mesh/D056648" }, { "@type": "ListItem", "position": 5, "name": "Granulomatose avec polyangéite", "item": "https://questionsmedicales.fr/mesh/D014890" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Granulomatose avec polyangéite - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Granulomatose avec polyangéite", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Granulomatose avec polyangéite", "description": "Comment diagnostiquer la granulomatose avec polyangéite ?\nQuels tests sanguins sont utilisés pour le diagnostic ?\nQuel rôle joue la biopsie dans le diagnostic ?\nQuels symptômes cliniques orientent vers cette maladie ?\nComment les examens d'imagerie aident-ils au diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Early+Detection+of+Cancer&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Granulomatose avec polyangéite", "description": "Quels sont les symptômes courants de cette maladie ?\nLa granulomatose affecte-t-elle les voies respiratoires ?\nQuels problèmes rénaux peuvent survenir ?\nY a-t-il des manifestations cutanées ?\nLes symptômes varient-ils d'un patient à l'autre ?", "url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Early+Detection+of+Cancer&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Granulomatose avec polyangéite", "description": "Peut-on prévenir la granulomatose avec polyangéite ?\nComment éviter les complications ?\nLes vaccinations sont-elles recommandées ?\nY a-t-il des conseils de mode de vie à suivre ?\nLes patients doivent-ils éviter certains médicaments ?", "url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Early+Detection+of+Cancer&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Granulomatose avec polyangéite", "description": "Quels traitements sont utilisés pour cette maladie ?\nComment les corticostéroïdes aident-ils ?\nQuels sont les effets secondaires des traitements ?\nLa thérapie biologique est-elle une option ?\nQuelle est l'importance du suivi médical ?", "url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Early+Detection+of+Cancer&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Granulomatose avec polyangéite", "description": "Quelles sont les complications possibles ?\nComment l'insuffisance rénale se manifeste-t-elle ?\nLes infections sont-elles fréquentes ?\nQuels problèmes pulmonaires peuvent survenir ?\nComment gérer les complications ?", "url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Early+Detection+of+Cancer&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Granulomatose avec polyangéite", "description": "Quels sont les facteurs de risque connus ?\nLe tabagisme augmente-t-il le risque ?\nLes infections peuvent-elles déclencher la maladie ?\nY a-t-il un lien avec d'autres maladies auto-immunes ?\nL'âge influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Early+Detection+of+Cancer&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la granulomatose avec polyangéite ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins, des biopsies et des examens d'imagerie." } }, { "@type": "Question", "name": "Quels tests sanguins sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent la recherche d'anticorps anti-PR3 et des marqueurs d'inflammation." } }, { "@type": "Question", "name": "Quel rôle joue la biopsie dans le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "La biopsie permet d'identifier les granulomes et l'inflammation des vaisseaux." } }, { "@type": "Question", "name": "Quels symptômes cliniques orientent vers cette maladie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs articulaires, des éruptions cutanées et des problèmes respiratoires." } }, { "@type": "Question", "name": "Comment les examens d'imagerie aident-ils au diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les examens comme la radiographie ou l'IRM montrent des anomalies dans les poumons et les reins." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de cette maladie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, fièvre, perte de poids, et douleurs musculaires." } }, { "@type": "Question", "name": "La granulomatose affecte-t-elle les voies respiratoires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des sinusites, des saignements de nez et des toux persistantes." } }, { "@type": "Question", "name": "Quels problèmes rénaux peuvent survenir ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des atteintes rénales peuvent entraîner une insuffisance rénale et des urines anormales." } }, { "@type": "Question", "name": "Y a-t-il des manifestations cutanées ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des éruptions cutanées, des nodules et des ulcères peuvent apparaître." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'un patient à l'autre ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité et la combinaison des symptômes peuvent varier considérablement." } }, { "@type": "Question", "name": "Peut-on prévenir la granulomatose avec polyangéite ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical peut aider." } }, { "@type": "Question", "name": "Comment éviter les complications ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un traitement précoce et un suivi régulier permettent de réduire le risque de complications." } }, { "@type": "Question", "name": "Les vaccinations sont-elles recommandées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccinations peuvent être recommandées pour prévenir certaines infections." } }, { "@type": "Question", "name": "Y a-t-il des conseils de mode de vie à suivre ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est conseillé." } }, { "@type": "Question", "name": "Les patients doivent-ils éviter certains médicaments ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent aggraver la maladie et doivent être évités." } }, { "@type": "Question", "name": "Quels traitements sont utilisés pour cette maladie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des corticostéroïdes et des immunosuppresseurs pour réduire l'inflammation." } }, { "@type": "Question", "name": "Comment les corticostéroïdes aident-ils ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils réduisent l'inflammation et soulagent les symptômes rapidement." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des infections, des troubles digestifs et des problèmes osseux." } }, { "@type": "Question", "name": "La thérapie biologique est-elle une option ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des thérapies biologiques ciblées peuvent être utilisées pour les cas réfractaires." } }, { "@type": "Question", "name": "Quelle est l'importance du suivi médical ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier est crucial pour ajuster le traitement et surveiller les complications." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'insuffisance rénale, les infections et les problèmes pulmonaires." } }, { "@type": "Question", "name": "Comment l'insuffisance rénale se manifeste-t-elle ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut se manifester par une diminution de la production d'urine et un gonflement." } }, { "@type": "Question", "name": "Les infections sont-elles fréquentes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients sont plus susceptibles de développer des infections en raison du traitement." } }, { "@type": "Question", "name": "Quels problèmes pulmonaires peuvent survenir ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des complications pulmonaires peuvent inclure des hémorragies et des nodules pulmonaires." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite un suivi médical étroit et des ajustements de traitement." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque connus ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, le tabagisme et certaines infections." } }, { "@type": "Question", "name": "Le tabagisme augmente-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque significatif pour cette maladie." } }, { "@type": "Question", "name": "Les infections peuvent-elles déclencher la maladie ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections, comme celles des voies respiratoires, peuvent être des déclencheurs." } }, { "@type": "Question", "name": "Y a-t-il un lien avec d'autres maladies auto-immunes ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes atteintes d'autres maladies auto-immunes peuvent avoir un risque accru." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "La maladie est plus fréquente chez les adultes jeunes à moyens, généralement entre 30 et 60 ans." } } ] } ] }

Sources (10000 au total)

A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.

Diagnosing gastric cancer (GC) while the disease remains eligible for surgical resection is challenging. In view of this clinical challenge, novel and robust biomarkers for early detection thus improv... The present 3-step study incorporated data from 2141 patients, including 888 with GC, 158 with chronic atrophic gastritis, 193 with intestinal metaplasia, 501 healthy donors, and 401 with other gastro... In discovery phase, one LR (GClnc1) was found to be up-regulated in both tissue and circulating EV samples with an area under the curve (AUC) of 0.9369 (95% confidence interval [CI], 0.9073-0.9664) fo... EV-derived GClnc1 serves as a circulating biomarker for the early detection of GC, thus providing opportunities for curative surgery and improved survival outcomes....

Optimal age to stop prostate cancer screening and early detection.

Prostate Cancer screening should be discontinued at older ages because competing mortality risks eventually dominate the risk of Prostate Cancer and harms exceed benefits. We explored the Prostate Can... We applied Bellman Equations to formulate the net benefits biopsy and "do nothing". Using difference between the net benefits of two alternatives, we calculated the stopping age. The cancer states wer... Our results suggested that Prostate Cancer screening stopping ages from the patient, healthcare system, and social were 70, 68, and 68 respectively. The univariate sensitivity analysis showed that the... Men should not be screened for Prostate Cancer beyond 70 years old, as this results in the net benefit of "do nothing" above the biopsy. Nevertheless, this finding needs to be further studied with mor...

Ovarian Cancer-Self Assessment: An Innovation for Early Detection and Risk Assessment of Ovarian Cancer.

The modality to detect ovarian cancer at an early stage is very limited. Early diagnosis determines the prognosis. This study aimed to develop a risk assessment tool for early detection of ovarian can... This study was carried out as a cohort study of patients diagnosed with suspected ovarian tumors undergoing cytoreduction operation at Hasan Sadikin Hospital, Bandung, from December 2019 to September ... In total, 115 patients included in this study. The differences were statistically significant in terms of the six variables (abdominal bloating, nausea/vomiting, decreased of appetite, fullness, menst... Risk assessments based on ovarian cancer self-assessment unfortunately were not comparable to postoperative histopathology as a single predictor. Ten variables in ovarian cancer artificial intelligenc...

Integration of multiomics features for blood-based early detection of colorectal cancer.

Early detection of colorectal cancer (CRC) significantly enhances patient outcomes. Conventional CRC screening tools, like endoscopy and stool-based tests, have constraints due to their invasiveness o... In this research, we harnessed the Mutation Capsule Plus (MCP) technology to profile an array of genomic characteristics from cfDNA procured from a single blood draw. This profiling encompassed DNA me... This model was subsequently validated in another cohort comprising 89 CRC patients and 95 healthy controls. Remarkably, the model achieved an area under the curve (AUC) of 0.981 (95% confidence interv... Our findings underscore the clinical potential of our multiomics liquid biopsy test, indicating its prospective role as a noninvasive method for early-stage CRC detection. This multiomics approach hol...

Prospective cohort for early detection of liver cancer (Pearl): a study protocol.

Hepatocellular carcinoma (HCC) is the fastest-rising and fourth most common cause of cancer death worldwide. Liver cirrhosis is the largest underlying risk factor for HCC. Therefore, patients with cir... This is a UK-based prospective, longitudinal, diagnostic, prognostic, multicentre, non-CTIMP study. Aiming to recruit 3000 patients with liver cirrhosis without a HCC diagnosis, the Pearl cohort will ... Ethical approval has been granted by REC and the trial is registered on ClinicalTrials.gov. The results will be published in peer-reviewed journals and presented at relevant meetings.... NCT05541601....